Tumour infiltrating lymphocytes therapy - RootPath
Alternative Names: InfiniTILTMLatest Information Update: 11 Jul 2023
At a glance
- Originator RootPath
- Class Antineoplastics; Gene therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 02 Jun 2023 Adverse events data from a phase I trial in Solid tumour presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 26 Mar 2022 Phase-I trials in Solid tumours in China (Parenteral) (RootPth pipeline, March 2022)
- 25 Mar 2022 Preclinical trials in Solid tumours in China (Parenteral) (RootPth pipeline, March 2022)